Skip to content
AwardedBelgiumGoodsFramework agreement

Omalizumab

Published
Published 26 March 2026
Deadline
Closed 29 April 2026

Overview

VITAZ vzw has awarded a framework agreement for the supply of Omalizumab pharmaceutical product to Novartis Pharma for EUR 388,000. The contract, awarded on 1 June 2026, establishes the terms and conditions for on-demand delivery of the medicine throughout the agreement period as specified in the technical specifications.

Key details

Country
Belgium
Status
Awarded
Category
Goods
Procedure
Open
Contract type
Framework agreement
Published
26 March 2026
Deadline
Closed
Classification (CPV)
Various medicinal products

Award outcome

Awarded value
€388,000
Award date
1 June 2026
Contract period
— → 11 May 2030
Winner
  • NOVARTIS PHARMA

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    3 June 2026

  2. Contract Notice

    26 March 2026

Contracting authority

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Omalizumab — won by NOVARTIS PHARMA — Skim